<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03726866</url>
  </required_header>
  <id_info>
    <org_study_id>186DDI18020</org_study_id>
    <nct_id>NCT03726866</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open Label, Repeated-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interactions and Safety Among D326, D337 and CKD-828 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate pharmacokinetic properties and drug interactions between D326 and D337
      co-administered groups, the CKD-828 alone and the total co-administered groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2018</start_date>
  <completion_date type="Anticipated">January 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax(Maximum plasma concentration of the drug at steady state)</measure>
    <time_frame>at Day 9</time_frame>
    <description>PK parameters of D326, D337 and CKD-828</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau(area under the plasma concentration-time curve for a dosing interval at steady state)</measure>
    <time_frame>at Day 9</time_frame>
    <description>PK parameters of D326, D337 and CKD-828</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax(Time to maximum plasma concentration at steady state)</measure>
    <time_frame>at Day 9</time_frame>
    <description>PK parameters of D326, D337 and CKD-828</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2(Terminal elimination half-life)</measure>
    <time_frame>at Day 9</time_frame>
    <description>PK parameters of D326, D337 and CKD-828</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 1</intervention_name>
    <description>D326, D337 or CKD-828 for 9 days</description>
    <arm_group_label>Sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 2</intervention_name>
    <description>D326, D337 or CKD-828 for 9 days</description>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 3</intervention_name>
    <description>D326, D337 or CKD-828 for 9 days</description>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 4</intervention_name>
    <description>D326, D337 or CKD-828 for 9 days</description>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 5</intervention_name>
    <description>D326, D337 or CKD-828 for 9 days</description>
    <arm_group_label>Sequence 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequence 6</intervention_name>
    <description>D326, D337 or CKD-828 for 9 days</description>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers aged between ≥ 19 and ≤ 40 years old

          2. Calculated body mass index(BMI) of ≥ 19 and ≤ 28kg/m²

          3. Subject who agree to use a combination of effective contraceptive methods or medically
             acceptable contraceptive methods from the date of first administration of
             Investigational product until completion of the clinical trial

          4. Subject who agree not to provide sperm

          5. Subject who voluntarily agree to participate in this study

        Exclusion Criteria:

          1. Any medical history that may affect drug absorption, distribution, metabolism and
             excretion

          2. Subject who has a clinically significant disease or history such as endocrine,
             gastrointestinal, cardiovascular, muscular disease.

          3. Genetic problems such as galactose intolerance, Lapp lactose dehydrogenase deficiency
             or glucose-galactose uptake disorder

          4. Subject who have received other clinical trial drugs within 90 days prior to the
             screening visit

          5. Any clinically significant active chronic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeong-Seok Lim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology and Therapeutics / Asan Medical Center, University of Ulsan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jihwan Oh</last_name>
    <phone>82-2-6373-0953</phone>
    <email>jihwan@ckdpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center, University of Ulsan</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dyslipidemias</keyword>
  <keyword>hypertension</keyword>
  <keyword>Drug-Drug interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

